An observational study in Diabetic Macular Edema, sponsored by University of Athens. Completed at 1 site in Greece. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by University of Athens · Observational
ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.
841 studies on the registry are indexed under Macular Edema; 56 are open to participants now.
This study's enrollment of 100 is close to the median of 97 across 163 observational studies indexed under Macular Edema.
Browse Macular Edema studies →University of Athens is the lead sponsor of 133 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with DME treated with intravitreal aflibercept 2.0mg in routice clinical practice.
Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatment
Exclusion Criteria:
Patients with other retinal diseases than DME Intraocular surgery within the last 6 months
Intravitreal aflibercept as used in the routice clinical practice
Change in best-corrected visual acuity
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Athens